psalexa
logo

Peripheral Artery Disease Therapeutics Pipeline Analysis

Peripheral Artery Disease Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11230
Available Format:

Peripheral artery disease is a condition in which plaque, comprising of fat, calcium, cholesterol, fibrous tissue and other substances present in the blood, build-up in arteries that supply blood to the brain, limbs and other organs. Atherosclerosis is a condition when plaques build-up in the arteries and limits the oxygen-rich blood flow to the body. Peripheral artery disease affects the leg arteries that can cause numbness and pain. In severe cases, gangrene (tissue death) can occur that can further lead to leg amputation. Bayer AG is in the process of developing rivaroxaban as a factor IXa inhibitors for the treatment of peripheral artery disease. Proteon Therapeutics, Inc. is in the process of developing vonapanitase as an extracellular matrix protein modulator for the treatment of the disease. Some of the companies having a pipeline of peripheral artery disease include Bayer AG, Proteon Therapeutics Inc., Juventas Therapeutics, Inc. and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry